Postmarket policy considerations for biosimilar oncology drugs.

Postmarket policy considerations for biosimilar oncology drugs.

Item
http://www.wikidata.org/entity/Q38693911
Improving access to high-cost cancer drugs in Latin America: Much to be done.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesSex differences in the risk of receiving potentially inappropriate prescriptions among older adultsKey drivers for market penetration of biosimilars in Europe.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Biosimilar biologic drugs: a new frontier in medical care.Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Policies for biosimilar uptake in Europe: An overview.Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
P2860

Postmarket policy considerations for biosimilar oncology drugs.

Item
http://www.wikidata.org/entity/Q38693911
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Postmarket policy considerations for biosimilar oncology drugs.
@en
type
label
Postmarket policy considerations for biosimilar oncology drugs.
@en
prefLabel
Postmarket policy considerations for biosimilar oncology drugs.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Postmarket policy considerations for biosimilar oncology drugs.
@en
P2093
P304
P31
P356
10.1016/S1470-2045(15)00381-2
P433
P478
P577
P698